Virax Biolabs Group (Virax Biolabs Group) ROCE % : -76.71% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Virax Biolabs Group's annualized ROCE % for the quarter that ended in Sep. 2023 was -76.71%.

Virax Biolabs Group ROCE % Historical Data

The historical data trend for Virax Biolabs Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group ROCE % Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

ROCE %

-141.20

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial			-	-	-195.14	-122.45	-76.71

Virax Biolabs Group ROCE % Calculation

Virax Biolabs Group's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-5.442	/	( ( (0.049 - 1.245)	+	(9.812 - 0.908) )	/ 2 )
	=	-5.442	/	( (-1.196	+	8.904)	/ 2 )
	=	-5.442	/	3.854
	=	-141.20 %

Virax Biolabs Group's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-5.808	/	( ( (9.812 - 0.908)	+	(7.025 - 0.787) )	/ 2 )
	=	-5.808	/	( ( 8.904	+	6.238 )	/ 2 )
	=	-5.808	/	7.571
	=	-76.71 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Virax Biolabs Group (NAS:VRAX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Virax Biolabs Group ROCE % Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.